×

CellRapeutics™ Serum from Multiple Myeloma Donor (XS-0426-XU131)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This serum is harvested from donors with plasma cell dyscrasia. It contains a pathological concentration of specific immunoglobulin light chains and a unique cytokine milieu, including elevated IL-6 and B-cell activating factor. This product is an essential resource for investigating malignant plasma cell biology, bone resorption signaling, and systemic humoral immune suppression.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • CellRapeutics™ Serum from Multiple Myeloma Donor
  • Cat. No.
  • XS-0426-XU131
  • Donor Age
  • Senior
  • Donor Health
  • Diagnosed with plasma cell dyscrasia. Serum is marked by the presence of monoclonal immunoglobulins or free light chains and biomarkers of bone marrow niche remodeling.
  • Ethnicity
  • Diverse backgrounds available.
  • Anticoagulant
  • None (separated via centrifugation following natural coagulation).
  • Additional Donor Information
  • Each lot features serum from donors with Multiple Myeloma. Profiles include M-protein levels, free light chain ratios, cytogenetic risk, and history of proteasome inhibitors or IMiDs.
  • Clinical Profile
  • Disease stage, M-protein type and level, plasma cell percentage in bone marrow, and history of chemotherapy or proteasome inhibitor treatment.

Additional Information

  • Medication History
  • Available upon request. Includes documentation of Proteasome inhibitors, Immunomodulatory drugs, Anti-CD38 monoclonal antibodies, and history of autologous stem cell transplantation.
  • Formulation
  • Frozen
  • Cell Viability
  • Cell-free (no residual erythrocytes or leukocytes).
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • Negative
  • Application
  • Drug Discovery, Immuno-oncology Research
  • Research Use Only
  • RUO
  • Quality Control
  • Each serum batch undergoes rigorous IRB-compliant screening, ensuring pathogen-free safety, consistent physicochemical properties, and standardized clinical characterization of disease-specific biomarkers to provide a reliable, high-purity biological matrix.
  • Storage
  • Store at -80°C or below for long-term stability, or at -20°C for up to 6 months, avoid repeated freeze-thaw cycles to preserve product quality.
  • Shiping
  • Dry Ice
  • Handling Notes
  • Thaw slowly on ice or at 4°C and centrifuge to remove cryoprecipitates, immediate aliquoting upon first thaw is recommended to maintain autoantibody functional integrity.
  • Warnings
  • Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.
  • Size
  • 1ML
  • Keywords
  • CellRapeutics™ Serum from Multiple Myeloma Donor, Serum, Multiple Myeloma

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Serum from Multiple Myeloma Donor (XS-0426-XU131). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.